Coral Laboratories Ltd

Coral Labs. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Coral Laboratories Ltd

₹ 384 0.95%
25 Apr - close price
corallab.com BSE: 524506
About

Incorporated in 1994 and headquartered in Mumbai – India Coral Laboratories Ltd is into the Manufacturing of Pharmaceutical formulations. The company manufactures Generic – Branded, Herbal Medicines, etc. in the product categories of Non-Sterile, Sterile, Nutraceuticals, Otc + Lifestyle, and it exports its products mainly to Ethiopia and other parts of the world.[1]

Key Points

Product Portfolio: [1]
The four important product categories include:
Non-Sterile: This comprises Capsules, Tablets, Dry syrup, etc. in Antibiotics/Anti-bacterial, Anti-fungal, Gastro-Intestinal Drugs, etc.
Sterile: This category includes Injectables, Eye Drops, Ear Drops, Nasal Sprays, and large volume Parenteral.
Nutraceuticals: The company provides a wide range of nutraceutical products such as dietary supplements, herbal / phytochemicals, multi-vitamins, and nutrients.
OTC+Lifestyle: The company provides products in the range of Female Hygiene, Contraceptives, Medical Devices, Skin Care, Infant & Child Care products, and Herbal products.

Website BSE
  • Market Cap ₹ 137 Cr.
  • Current Price ₹ 384
  • High / Low ₹ 498 / 225
  • Stock P/E 15.0
  • Book Value ₹ 482
  • Dividend Yield 0.00 %
  • ROCE 5.38 %
  • ROE 4.13 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Stock is trading at 0.80 times its book value
  • Debtor days have improved from 147 to 109 days.

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • The company has delivered a poor sales growth of -3.32% over past five years.
  • Company has a low return on equity of 6.61% over last 3 years.
  • Earnings include an other income of Rs.5.63 Cr.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations

Edit Columns
Loading peers table ...

Quarterly Results

Figures in Rs. Crores

Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
28.34 27.82 23.79 18.42 13.33 20.08 16.25 25.70 24.73 11.44 13.55 23.15 18.08
23.34 25.64 17.54 17.43 13.42 19.03 15.52 21.39 23.88 13.52 11.81 17.00 15.98
Operating Profit 5.00 2.18 6.25 0.99 -0.09 1.05 0.73 4.31 0.85 -2.08 1.74 6.15 2.10
OPM % 17.64% 7.84% 26.27% 5.37% -0.68% 5.23% 4.49% 16.77% 3.44% -18.18% 12.84% 26.57% 11.62%
0.47 2.06 1.50 0.85 0.94 2.49 2.03 2.21 1.54 1.16 1.29 1.81 1.37
Interest 0.01 0.03 0.06 0.02 0.01 0.05 0.10 0.11 0.11 0.02 0.00 0.00 0.00
Depreciation 0.47 0.50 0.50 0.49 0.51 0.50 0.50 0.50 0.50 0.68 0.55 0.44 0.49
Profit before tax 4.99 3.71 7.19 1.33 0.33 2.99 2.16 5.91 1.78 -1.62 2.48 7.52 2.98
Tax % 7.21% 53.10% 19.33% 66.92% 27.27% 14.72% 26.39% 17.26% 51.69% 45.06% 26.21% 20.21% 27.52%
4.63 1.74 5.80 0.45 0.25 2.55 1.59 4.89 0.86 -0.89 1.84 6.00 2.16
EPS in Rs 12.96 4.87 16.23 1.26 0.70 7.14 4.45 13.69 2.41 -2.49 5.15 16.79 6.05
Raw PDF

Profit & Loss

Figures in Rs. Crores

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
39.95 41.51 50.75 59.39 76.94 95.47 92.47 91.08 70.58 96.57 75.61 78.12 66.22
32.37 33.96 40.65 47.05 60.46 72.14 77.13 78.66 65.16 80.72 67.39 74.30 58.31
Operating Profit 7.58 7.55 10.10 12.34 16.48 23.33 15.34 12.42 5.42 15.85 8.22 3.82 7.91
OPM % 18.97% 18.19% 19.90% 20.78% 21.42% 24.44% 16.59% 13.64% 7.68% 16.41% 10.87% 4.89% 11.95%
0.89 1.41 1.21 2.59 2.89 2.99 4.47 5.16 5.89 3.79 5.77 6.93 5.63
Interest 0.12 0.12 0.10 0.15 0.24 0.20 0.20 0.17 0.19 0.04 0.14 0.34 0.02
Depreciation 1.27 1.27 1.24 2.57 1.73 1.56 1.56 1.90 2.01 1.98 1.99 2.18 2.16
Profit before tax 7.08 7.57 9.97 12.21 17.40 24.56 18.05 15.51 9.11 17.62 11.86 8.23 11.36
Tax % 20.34% 20.34% 21.06% 21.62% 28.79% 33.67% 31.02% 34.11% 21.84% 23.04% 23.69% 21.63%
5.65 6.03 7.87 9.57 12.40 16.30 12.45 10.22 7.13 13.55 9.05 6.45 9.11
EPS in Rs 15.81 16.88 22.03 26.79 34.71 45.63 34.85 28.61 19.96 37.93 25.33 18.05 25.50
Dividend Payout % 9.48% 8.88% 9.07% 9.33% 8.64% 10.95% 5.73% 6.99% 0.00% 0.00% 0.00% 0.00%
Compounded Sales Growth
10 Years: 7%
5 Years: -3%
3 Years: 3%
TTM: -24%
Compounded Profit Growth
10 Years: 1%
5 Years: -12%
3 Years: -3%
TTM: 1%
Stock Price CAGR
10 Years: 15%
5 Years: 3%
3 Years: -3%
1 Year: 47%
Return on Equity
10 Years: 10%
5 Years: 7%
3 Years: 7%
Last Year: 4%

Balance Sheet

Figures in Rs. Crores

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 3.57 3.57 3.57 3.57 3.57 3.57 3.57 3.57 3.57 3.57 3.57 3.57 3.57
Reserves 34.57 39.97 47.00 55.50 66.61 105.59 112.76 110.20 112.10 133.07 152.48 151.23 168.47
0.01 0.52 0.20 1.37 0.37 2.17 1.74 1.44 5.91 6.25 6.04 0.00 1.47
10.78 14.18 9.73 11.98 18.92 19.79 22.12 20.57 22.71 24.65 27.80 19.55 25.31
Total Liabilities 48.93 58.24 60.50 72.42 89.47 131.12 140.19 135.78 144.29 167.54 189.89 174.35 198.82
21.69 20.78 19.74 18.92 18.09 18.23 22.31 23.23 22.56 21.44 23.78 25.26 24.34
CWIP 0.00 0.00 0.00 0.00 0.00 0.23 0.00 0.00 0.00 0.50 1.72 0.00 0.00
Investments 1.17 1.17 1.17 1.17 4.58 38.60 44.98 28.06 24.87 33.18 46.18 41.29 51.53
26.07 36.29 39.59 52.33 66.80 74.06 72.90 84.49 96.86 112.42 118.21 107.80 122.95
Total Assets 48.93 58.24 60.50 72.42 89.47 131.12 140.19 135.78 144.29 167.54 189.89 174.35 198.82

Cash Flows

Figures in Rs. Crores

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
2.96 0.10 1.03 0.37 5.05 10.77 13.47 -0.88 -3.86 0.93 6.08 12.67
0.14 0.42 0.82 -0.47 -2.73 -9.80 -13.21 3.23 -1.55 -0.07 -6.05 -2.61
-0.02 0.47 0.00 -0.02 -0.05 0.47 -2.62 -1.18 3.56 0.35 0.15 -6.43
Net Cash Flow 3.08 0.99 1.85 -0.11 2.28 1.45 -2.36 1.17 -1.86 1.21 0.18 3.62

Ratios

Figures in Rs. Crores

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 64.59 93.21 108.89 152.29 131.93 117.14 124.77 121.51 177.95 148.01 183.97 109.43
Inventory Days 104.84 123.81 97.13 109.53 109.50 155.46 119.55 116.25 175.98 158.00 168.72 99.73
Days Payable 72.50 97.13 60.85 65.80 79.84 75.22 87.33 91.30 128.93 107.76 80.87 33.59
Cash Conversion Cycle 96.94 119.88 145.16 196.02 161.59 197.39 156.99 146.45 225.00 198.25 271.82 175.56
Working Capital Days 98.49 143.06 159.31 202.07 180.65 171.85 167.72 176.85 241.35 201.83 251.46 221.42
ROCE % 20.17% 18.71% 21.24% 22.23% 26.93% 27.64% 15.91% 13.44% 7.86% 13.34% 7.24% 5.38%

Shareholding Pattern

Numbers in percentages

Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
71.51% 71.51% 71.51% 71.51% 71.51% 71.51% 71.51% 71.51% 71.51% 71.51% 71.51% 71.51%
0.42% 0.42% 0.42% 0.42% 0.42% 0.14% 0.14% 0.14% 0.14% 0.14% 0.14% 0.14%
28.07% 28.07% 28.07% 28.07% 28.07% 28.34% 28.34% 28.34% 28.35% 28.34% 28.35% 28.35%
No. of Shareholders 4,0204,2374,4254,3884,3174,2184,1104,0464,0403,9814,0054,098

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports